Lindsay Rosenwald

lindsayrosenwald Lindsay Rosenwald Investing in the Future ofLife Sciences and Healthcare

2011-06-08T03:45:00.000-07:00

OpusPoint Partners is an innovative new company with a unique vision for the future of the life science and healthcare industry. That vision includes some cutting edge technologies but also some forward thinking business philosophies.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare
Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

Lindsay Rosenwald MD OpusPoint Partners Investing in the Future ofHealthcare and Life Sciences

2011-06-08T02:40:00.000-07:00

OpusPoint Partners:

Investing in the Future ofHealthcare and Life Sciences

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar's oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology. By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals. Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.

At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses. Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.
For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.
The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.
The Benefits of Making the World a Better Place

The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money. It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone. This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

A Step Forward In The Late-Stage Prostate Cancer Treatment

2011-02-26T05:12:00.000-08:00

In 2009, Johnson & Johnson successfully acquired Cougar Biotechnology, Inc., a Lindsay Rosenwald’s portfolio company focused on oncologic research and innovations. The acquisition was completed while Cougar Biotechnology conducted its 2 Phase III trials of a late-stage prostate cancer agent, abiraterone acetate. The first trial showed good results in patients with castration-resistant prostate cancer progressed after docetaxel-based chemotherapy. The second Phase III trials are being held in patients who haven’t received chemotherapy yet.

Statistics shows that one in six men is at the risk of prostate cancer, which is 10 % of all cancer-related fatal outcomes in the US.

Cougar Biotechnology, funded by Dr. Lindsay Rosenwald, one of the leading investors in the biotechnology field, operates as a subsidiary of J&J and is going to cooperate with a unit of Centocor Research & Development, Inc. - Ortho Biotech Oncology Research & Development.

According to Dr. William N. Hait, Global Therapeutic Head at the Ortho Biotech Oncology Research & Development, the investments by Lindsay Rosenwald and a further acquisition of Cougar Biotechnology strengthened the positions of Cougar and Johnson & Johnson in the global oncology market. Abiraterone acetate is a step forward in prostate cancer treatment. By targeting cancer cells, the agent combined with prednisone/prednisolone creates microenvironment that prevents and even reduces the size of the tumor, thus significantly improving overall survival in patients with advanced metastatic prostate cancer.

Based on the results of a randomized Phase III COU-AA-301 trial, J&J is going to file acceptance applications for this new discovery, abiraterone acetate. The data analysis of the trial shows that the patients, who received abiraterone acetate and low doses of prednisone/prednisolone, experienced improvements in overall survival. 1 195 men with metastatic advanced prostate cancer (also known as castration-resistant prostate cancer or CRPC) took part in the trial. All these patients were previously treated with a docetaxel-based chemotherapy.The results were shown in late 2010 at the 35th Annual European Society for Medical Oncology (ESMO) Congress. According to the data received, there was a 35 % death reduction observed and a 36 % increase in average survival compared with the placebo group.

Furthermore, patients taking abiraterone acetate plus a low dose of prednisone/prednisolone had a significant improvement of time to PSA progression (or TTPP), while their life extended to 10.2 months compared to median 6.6 months for placebo. Total prostate-specific antigen response was achieved in 38 % of men, who received abiraterone, compared to only 10 % in the placebo plus prednisone/prednisolone group.

Abiraterone acetate demonstrated its low toxicity and less adverse effects than placebo plus prednisone/prednisolone. Among the adverse effects were water retention and hypokalemia. In addition, liver dysfunction was observed in 10 percent of abiraterone treated patients compared to 8 percent in the placebo and prednisone/prednisolone group. Abiraterone acetate patients had 12.5 percent of cardiac disorders compared to 9.5 percent of placebo patients. These adverse effects are much less toxic than those that are normally associated with docetaxel-based chemotherapy.

Dr. Johann S. de Bono, one of the lead investigators in the COU-AA301 trial, as well as Dr. Lindsay A. Rosenwald, one of the main investors in the biomedical and biotechnology sector, believe that abiraterone acetate has a significant potential to meet the oncology needs. The drug demonstrated its ability to inhibit cancer cells and extend overall survival in patients with castrate-resistant prostate cancer that progressed after chemotherapy.

Marketing applications are planned to be filed by Johnson & Johnson by the end of the year in the United States and Europe and then in the rest of the world. The approved abiraterone acetate will be commercialized and sold by Centocor Ortho Biotech Inc. in the U.S. and by Janssen Pharmaceutical worldwide.

Prostate cancer takes the 5^th place among the most common cancers and represents a big health problem. The results of the COU-AA-301 trial are very important for men with castration-resistant prostate cancer, since they previously had very few treatment options and a poor prognosis according to Dr. Howard I. Scher, one of the lead Phase III COU-AA-301 trial investigators.

Investments by Lindsay Rosenwald and his portfolio companies promote early access to novel anti-cancer agents like abiraterone acetate and make them eligible for patients worldwide. Being an important medical advance, abiraterone acetate is a great step forward in the oncology therapeutic options that improve the quality of life as well as overall survival in patients with metastatic advanced prostate cancer.

J&J’s AbirateroneProlongs Life in Advanced Prostate Cancer Patients

2011-02-24T07:36:00.000-08:00

According to a Phase 3 clinical trial presented at the 35^th meeting of the European Society for Medical Oncology in Milan, after being treated with abiraterone acetate, a novel drug by Johnson & Johnson, patients with metastatic prostate cancer live about 4 months longer compared to the patients with the same disease and treated with a placebo.

J&J revealed its trial results last month and demonstrated the positive effect of abiraterone. It also said that it would seek the approval of the drug by FDA by the end of the year.

The research and design of abiraterone acetate was initially funded by Lindsay Rosenwald, MD, who saw a great prospect in the drug candidate. Along with his researchers and analysts, Dr. Rosenwald made investments in the promising prostate cancer drug and this was the first step towards its clinical trials and further approval by FDA. Being one of the most productive businessmen and financial investors in the biotechnology sector, Lindsay Rosenwald supports the development of innovative promising drugs and nanotechnologies expanding the horizons of the modern medicine. By investing in the original research and trials by Cougar Biotechnology, which was acquired by J&J in 2009, Lindsay Rosenwald promoted indirectlythe development of abiraterone giving more chances to advanced prostate cancer patients.

The Phase 3 trial included 1,195 patients with advanced prostate cancer, where 398 patients received abiraterone plus prednisone treatment, while 797 patients were treated with a placebo plus prednisone. All the men, who took part in the trial, were diagnosed with metastatic castrate-resistant prostate cancer, whose condition wasn’t improved after hormonal therapy or docexatel-based chemotherapy.

About 35% of patients, who took abiraterone acetate, had improved survival rate. They lived median 14.8 months compared to those treated with a placebo plus prednisone, who lived median 10.9 months. The difference in survival shows that abiraterone significantly prolongs life.

The principle of the drug’s work lies in its ability to reduce the production of male hormones, including testosterone, which fuels the tumor cells and promotes their growth in different parts of the body. The initial stages of prostate cancer are usually treated with hormonal therapy aimed at inhibiting testosterone production and reducing the speed of tumor growth. However, most prostate cancers eventually become resistant to hormonal therapies and the tumor starts growing again.

J&J’s Phase 3 study demonstrated promising treatment results in patients with advanced metastatic prostate cancer unresponsive to hormonal therapy or docexatel-based chemotherapy. Such patients are called third-line patients and they have very poor survival and almost unsuccessful treatment. J&J also investigates cases with prostate cancer patients who have yet to undergo their chemotherapy. These are similar patients, who were tested in a study of another anti-cancer drug, Provenge by Dendreon.

Another abiraterone’s competitor is Jevtana owned by Sanofi-Aventis, which showed a median survival of 15 months compared to median 12.7 months for men receiving mitoxantrone, another chemotherapy regime.

The Online Mentioning of Lindsay Rosenwald

2010-08-04T05:19:00.000-07:00

*A member of the Board of Directors at the Republican Jewish Coalition, Dr. Lindsay Rosenwald is a highly informed and well connected man in the biotechnology investing and financing arena. Dr. Rosenwald provides contributions to hedge funds, venture capital, and private equity as the head of Paramount Capital. You may read his biography can be read on the RJC official website at: www.rjchq.org.

*Dr. Lindsay Rosenwald’s relationships between the Republican Jewish Coalition and the Paramount Capital Asset Management Inc. are listed as map relationships on the MucketyMaps site.

*If you search for Dr. Lindsay Rosenwald on the Huffington Post’s FundRace 2008, you’ll see references regarding his contributions of $61,800 to the John McCain Victory Committee.

*In the Wellness.com online community, you’ll find many honorable mentions of Dr. Lindsay Rosenwald. As a practitioner in NYC, Dr. Rosewald graduated from the medical school at Temple University. As part of his practice, he offers physical exams, fitness instruction and programs, cholesterol and bone density testing, immunizations, skin biopsies, treatment for menopause, stress reduction and other ongoing treatment evaluations.

*An honorary member of the Jewish Orthodox Youth Hockey Organization’s NyIceCats, Dr. Lindsay Rosenwald was presented with gifts from the team by Neil Herskowitz, Director at Manhattan Pharmaceuticals, Inc. at the 3rd Annual Captain’s Dinner in Le Marais on March 12th. During the meal, Dr. Rosewald announced that he was hoping for another 25 years of ice time at the Piers. The dinner was over after the ceremony of the “Golden Balls” awards.

Dr. Lindsay Rosenwald is a unique person to travel successfully in two different boats of life sciences and financial investments

2010-06-14T02:41:00.000-07:00

As soon as completing the professional course in medicine at Pennsylvania State University in the year 1973, Dr. Lindsay Rosenwald started his medical practice. He has done his graduation from Abington High School before he joined at the Pennsylvania State University for professional course. Later he got admitted in to Beta Gamma Sigma. It is a society for business schools honors. In the year 1977, he completed his graduation in the subject of finance and he was awarded a bachelor’s degree in that year. Though he has high curiosity and aptitude, Rosenwald always preferred to be a doctor and hence practiced medicine for some years.

Rosenwald had a dream to become a doctor and in this direction he got an admission for himself in the medical school, named as Temple University. He studied medicine course at this university only. After successful completion of theoretical classes, he had to join an internship course for practical knowledge. For this purpose, Rosenwald joined Abington Medical Center. He had completed his internship course of one year. After the completion of internship course, he has started his own medical practice. He continued to work as a physician for almost two and half years. Lindsay Rosenwald was interested in medical practice. But then he used to feel something deficient in his way. So, he decided to combine his other interests to medicine. He soon developed uniqueness to practice both the jobs of his interest. One is being a physician while other is to serve as an analyst. Rosenwald was among the very few persons of that time, who practiced both the jobs at a time. He not only worked in both the jobs, he has also witnessed success in both of them. Later he left his own practice in 1986 when he decided to go to the Wall Street. There was a common notion that doctors are not well suited for the profession or job of investments. This traditional opinion was broke up by Rosenwald with his whooping success in both the fields. He had the knowledge of life sciences and also financial world. This made to implement the knowledge of one aspect to the other. In this way, he was successful in implementing the finance and investment knowledge to the medical field. He had brought investments to the medical field for the purpose of developing new drugs and the companies that concentrate on the development of new drugs.

In the same way, Lindsay Rosenwald was also successful in improving the corporate business under the name of Paramount group of companies, by bringing the drugs in to the business. He had established a good number of companies serving the fields of life sciences and corporate business. Many drugs are in the stage of clinical trails, which are developed by the portfolio companies of the Paramount group. The main companies of the Paramount Capital are Paramount Bio Sciences, Paramount Bio Capital and Paramount Corporate Development. Paramount Capital has supported more than twenty five new budding companies in this field in the last three years.

2010-06-11T06:33:00.000-07:00

Paramount BioSciences, LLC (“Paramount”) is known as a top pharmaceutical drug development and investment organization having its principal concentration on the biotechnology and life sciences sectors. By using Paramount BioCapital, Inc., a FINRA listed broker-dealer in head of initial funding and raising capital for Portfolio firms, Paramount BioSciences intensely contributes to the emergence and development of modern biotechnologies and life sciences.

Paramount BioScienses’ Structure

Not only does Paramount BioSciences provide specialized services and assistance, but is also engaged in new product enhancement, biotech companies purchase and advancement. It helps the newly created businesses in a number of value-adding methods. They assess solution prospects for the organizations; produce growth plans to facilitate the creation process ahead of, during, as well as following the creation of Portfolio Firms. Equally, back-up and expertise is thoroughly supported by BioSciences as it permits its Portfolio Corporations to access to a lot more knowledgeable infrastructure than they may have. This allows the corporation administration to pay attention to the medicine candidates’ growth as opposed to building their unique infrastructure. In lots of ways, this model developed by Paramount’s originator Lindsay Rosenwald gives both expert and “back office” support and limits delays in the creation procedure, as well as maximized the earnings for Portfolio companies and the customer group.

Following acceptance and in-licensing, a devoted administration team throughout the full development cycle generally works on drug candidates. Senior medicine development employees at Paramount BioSciences, including Lindsay Rosenwald, help Portfolio Organizations in most aspects of pharmaceutical drug creation. This includes formulation, medical development, toxicology, production, quality assurance, and commercialization. Because of their extensive working experience in creating top prescription products, the Paramount’s staff gives options for a selection of therapeutically clues, starting from inflammation to cardiovascular system to oncology to neurology and several other signs. Worldwide network of experts in addition to business frontrunners in the medical and research communities provide guidance throughout the candidates’ growth and approval cycle.

Along with an established track record, Paramount BioSciences assists Portfolio Corporations recruit employees that will guide the fresh corporations created around the new compounds. One of several recent hires at Portfolio Organizations, you can find such executives as the past CEOs of Roche, Biogen, Sanofi-Aventis, Johnson&Johnson, Amgen and many more.

More than 20 years of financing and progression of biomedical firms throughout a wide range of therapeutic signs, Lindsay Rosenwald is head of Paramount BioSciences' more than 40 biotech firms. He forms firms from the nothing making use of his own capital after which funds are raised through various confidential individuals through Paramount Capital.

Paramount handles such critical capabilities as accounting, legal, market analytical, financial capabilities. This assists its Portfolio firms to focus on medical studies and generating value for shareholders, licensors and patients.

With such a keen eye for locating and constructing modern drug treatments, Paramount BioSciences raises the standard and promises of drug candidates across the world, from tiny biotech organizations and educational centres to big pharmaceutical businesses.

Paramount Approach To Value Generation

Exactly what tends to make Paramount BioSciences get noticed is that their structure and external network allows them to support Paramount Incubated Firms until finally they become self-sufficient. The production routine has been developed by Lindsay Rosenwald in 1998 and can be referred to in a simple scheme similar to this one:

Product Property --> Paramount Preliminary Funding and Expansion --> Incubation --> Portfolio Company Formation --> Cost Inflection Stage

Workers for each Portfolio Corporation are hired in compliance with developmental and fiscal circumstances. Typically, the majority of staff at Paramount currently has a minimum of 15 years of practical experience in biotechnology or health care sectors maneuvering drug prospects throughout the regulatory and clinical value cycle. Their expertise runs from molecular biology to clinical medicine.

With this kind of strong expertise through the drug development business, Lindsay Rosenwald has been able to produce the staff with leadership roles within the biotech market with numerous pharmaceutical products being sold globally, including Viracept, Neulasta, Rituxan, and Kepivance.

Paramount Sections

Paramount Biosciences

With around forty five staff members in 8 offices internationally, Paramount BioSciences contend and negotiate for higher education and business biotechnology entitlements. It develops and in-licenses materials for various restorative signs - from inflammation and cardiology to neurology and cancer. Lindsay Rosenwald helps construct standalone biotech firms, which could attract capital and succeed as publicly traded corporations

Paramount BioCapital, Inc.

Paramount BioCapital Inc. is a NASD-registered dealer that solicits money for the Portfolio Organizations. It brought in above $1 billion and around $200 million in 2009. With their extensive know-how in securities purchases such as “PIPEs”, reverse takeovers, self-registrations and private placements, Paramount BioCapital has become the leader inside the biotechnology capital market.

Paramount Improvement

Lindsay Rosenwald works closely with Paramount Corporate Development, which is associated with in-licensing and drug development pursuits. The Business Development group includes twenty sector experts with a huge knowledge in most aspects of drug advancement, including formulation, scientific operations, production and commercialization.

Paramount BioCapital Property Management

Property Management is responsible for acquiring and disseminating equities of global health care businesses. They have a proven hedge fund framework and property under management in various private positioning vehicles.

Paramount Purchasing Corporation

Paramount Acquisition Company makes distinctive private equity vehicles that match substantial capitals with late-stage non-public businesses. It recently announced a $54 million transaction with Valeritas, which is a medical device company having its key FDA-approved insulin pump h-Patch.

Paramount BioSciences Executive Management Team

On average, Paramount BioSciences personnel possess 15 years of strong working experience within the medical and regulatory functions. Headed by Lindsay Rosenwald, the associates took part in dozens of prescription advancement and commercialization assignments, including Rituxan, Viracept, Sutent, Kepivance, and Neulasta. More than fifty chemical substances currently undergo specialized medical development process and the products contain drug treatments throughout a broad selection of signs that include neurological diseases, metabolic problems, transmittable diseases and cancer.

Lindsay Rosenwald, M.D., is CEO and Chairman at Paramount BioSciences. His extensive working experience within biotechnology, pharmacology and finance made him one of the frontrunners in the biotechnology and life sciences industries. With more than twenty years of past experiences in developing and investing in biotechnology and life science companies, Dr. Lindsay Rosenwald set up and nurtured more than 40 biotech/pharma businesses.

J. Jay Lobell, J.D., is President and Chief Operating Officer at Paramount BioSciences. His previous knowledge includes partnership at Covington & Burling, where he supplied economic, regulatory, business, and litigation advice to financial organizations, firms and individuals.

Russell Ellison, m.d., is Executive Vice President with over 33 years of senior management experience in pharmaceutical advancement and marketing he is a former vice president clinical development at fibrogen, inc. and chief healthcare officer of sanofi-synthelabo, usa. Dr. Ellison additionally served as the us. Vice president of medical affairs and is a former we. Vice president, medical affairs and chief medical officer of Hoffman la ruche.

Advantages of Paramount BioSciences Style

Exactly what makes Paramount BioSciences a preferred acquirer of prescription drugs and developer of biotechnologies is that Lindsay Rosenwald’s development team along a world-wide corporate progression team that assesses and helps unit and market opportunities. The offices of Paramount BioSciences are located around the world, which includes New York City, London, Boston, Shanghai, San Diego, North Carolina, Orange County (California)). Promising drug candidates are shifted forward rapidly in the accreditation process. Reps of all areas in drug development cycle interact to make certain an understanding to move forward. The next phase is the generation of product development plans for the compound and hiring supervision personnel. At this stage, the substances are transferred to Portfolio Organizations with no transitional delay. The product candidates are supported throughout the specialized medical and regulatory procedure.

Paramount BioSciences has proved to rapidly perform offers and commence creation work. Its access to financing is an integral part of any product development. It provides Portfolio businesses with the construction that promotes drug candidate’s progression through to marketplace, getting rid of odds of program becoming stalled.

Medical and commercial expertise at the business stage assists Paramount Portfolio companies increase value to in-licensed items.

Background regarding Financial Wherewithal

Paramount BioSciences underneath the direction of Lindsay Rosenwald has produced over $1 billion from outside shareholders in addition to their own investment in Paramount’s portfolio companies. All organizations and medical research financed through the company get substantial financing on all levels of the creation cycle.

Linsay Rosenwald has normal and close interaction with the leading US sell-side and buy-side organizations that consist of notable medical care investors, with whom Paramount’s hedge funds invest in the deals not directly involving this company itself. Paramount’s personnel possess real-time knowledge of health care capital markets, which resulted in over $400 million funds for Portfolio Businesses in 2009 year alone, including $200 million by Paramount. This includes $47 million for Cougar Biosciences in conjunction with SG Cowen, $37 million for Ziopharm Oncology, $22 MM for Chelsea Therapeutics and $16 million for Innovive Pharmaceuticals. Many of the top health care funds borrowed in Paramount this year, which is always an excellent indication for the introduction of biotechnology and life sciences sectors.

Lindsay Rosenwald Accomplishments

2010-05-17T09:59:00.000-07:00

Lindsay Rosenwald began his professional studies at Pennsylvania State University in 1973 after graduating from Abington High School. He excelled a business and was particularly fascinated with economics and finance. He was a member of Beta Gamma Sigma, the business school’s honors society. In 1977, he graduated with his Bachelors degree in Finance. Despite his aptitude and interest in business, Lindsay Rosenwald had always wanted to be a doctor.

In pursuit of his lifelong dream, Rosenwald entered Temple University’s School of Medicine. After graduating from Temple University in 1983, he began an internship at Abington Hospital before starting his own private practice. He worked as a physician in his practice for two and a half years. Though he enjoyed being a doctor, Rosenwald desired a career where he could combine his two loves – medicine and business.

Lindsay Rosenwald left his private practice in 1986 to head to Wall Street where he took on a position as a Physician / Analyst, a very unique position with only a few people doing it at the time. Despite the stereotype that doctors do not make good investors, Dr. Rosenwald excelled at this position. He worked here because he felt it was important to focus on investments in the healthcare industry. People admired him and respected his opinions and expertise. While he missed treating patients, he knew this was where he belonged. During this time, he also worked for D.H. Blair and Company, a private investment company, as the managing director of corporate finance. After a few years, he left D.H. Blair and Company to focus on a new project and company.

In 1991, Lindsay Rosenwald founded Paramount Biotech. Over time, he has expanded this company by starting new companies and gaining control of other biotech companies. It has created or financed over 40 companies – over 25 of which have been in the past three years. He builds these companies by focusing on the growth of both the corporate and biotechnology portions. Now, Paramount Capital is comprised of many companies. These companies include Paramount Biosciences, which creates and supports new biotechnology companies, Paramount Corporate Development, which works to build the Paramount Corporation as well as develop new drugs, and Paramount BioCapital, a broker-dealer which has raise over $950 billion in profit since it started. The companies that Rosenwald controls have licensed or acquired over 100 experimental stage medicines.

Perhaps one of Dr. Rosenwald’s greatest achievements is that he set the record for the quickest development of a drug. In only 30 months, Arsenic Trioxide was developed and approved by the FDA for the treatment of a deadly form of leukemia. This drug has been on the market worldwide for over a decade and has saved and extended thousands of lives.

Lindsay Rosenwald has been revolutionary with the companies he has created. In one of the greatest reverse mergers of all time, his company, Cougar Biotechnology, sold for over $1 billion to Johnson and Johnson, despite only having a single drug with phase 2 clinical data. He has also founded the first publicly traded stem cell company, gene therapy company, and cancer vaccine company. Under Rosenwald’s leadership, his companies have developed countless groundbreaking drugs, including Peramivir for H1N1 Influenza, Fanapt for schizophrenia, Savella for fibromyalgia, and Trisinox for acute leukemia. He is also responsible for the first successful anti-obesity drug developed in the United States market in 30 years.

One of the reasons that Rosenwald’s companies have been successful is that he hires PHDs, MDs, MBAs, and other experts to serve as his senior level professionals. These people bring a great amount of experience in both the medical and business arenas which helps make his companies stronger and more diverse. They strive to develop new medicines with great focus and efficiency. These companies are blazing the trail of new medicines and treatments that will change the practice of medicine. He has also created the Rosenwald Foundation which has donated millions of dollars to medical and science instruction to help build the future of medicine.
Dr. Lindsay Rosenwald is the world’s most prolific entrepreneur in the history of the biotechnology industry. People attribute the success of biotechnology on Wall Street in the last 30 years to him. His personal assets total greater than $600 million. In 2002, Rosenwald topped the list of Genetic Engineering News’ 100 Molecular Millionaires.

Lindsay Rosenwald has built his business by constantly looking towards the future and now is no exception. Dr. Rosenwald believes that there will continue to be rapid growth in the biotechnology industry over the next twenty years. At the rate it is developing, this growth will be exponential. According to Rosenwald, future medical breakthroughs will come through small biotech companies that are focused in on producing only a few products, rather than a giant biotech company that has many projects in work at once. Rosenwald believes that focus should now be placed on finding treatments for two of society’s biggest medical threats – heart disease and cancer.

Dr. Lindsay Rosenwald - A Pioneer in Biotechnology and Finance

2010-05-02T03:54:00.000-07:00

Dr. Lindsay Rosenwald is an eminent researcher and financer in the present era. He has attained the position of famous corporate finance in the field of Biotechnology. He commands 20 years of experience in the research and development of Biotechnology and industrial finance simultaneously. He is one of the fore runners in the field of Biotech Industry. He contributed a lot for the research and development in Biotech and Pharmaceutical Industry. He is the pioneer in the industry of Biotech. From last 20 years he has been engaged in diversified financial Portfolio. Financial Portfolio is a feather in his cap and enabled him to attain success after success smoothly. His Portfolio consists of Industrial finance, Venture capital, Merchant and Investment banks, Asset management etc.

Dr. Lindsay Rosenwald is the head of the Paramount Group of Companies. He is the acting as President or Director or CEO in all of them. Under his leadership there group of companies fared extremely well. Most of the Paramount Group of Industries is engaged in research in Biotechnology and advanced Clinical Development and Drug designing. He also established Rosenwald Foundation a charitable foundation. He is the President of that foundation. This foundation assists other small companies and people who are engaged in this field of Biotechnology. Dr. Lindsay Rosenwald with his diversified experience in the twin fields of Biotechnology and Finance he has become Director in many public and private companies across the globe.
A glance at Dr. Lindsay Rosenwald academic career shows that he accomplished finance degree and later completed his under graduation in Bachelor of Science from Pennsylvania state university in 1977. After that he obtained a medical degree from Templeton University. Later he completed his internship course and started private medical practice and continued it for 2 years. After that with his sufficient knowledge in the field of Medicine and Finance he shifted to Wall Street. This became a turning point in his career. He started a new career as an entrepreneur. Dr. Lindsay Rosenwald diversified knowledge in the fields of Medicine and Finance has elevated him to the position of legend in the fields of biotechnology and finance within a span of 20 years. Paramount BioCapital, first company established by him which is engaged in accumulating funds and satisfy the financial needs of the Paramount Group of Companies. Sooner Paramount BioCapital has become a leading Capital Venture and Industry Finance Company is a grand success. Paramount BioCapital has successfully raised about 1 billion dollars for the Paramount Group of Companies.
Dr. Lindsay Rosenwald with his 20 years of vast experience brought revolutionary change in the field of Biotechnology in the world. He is a pioneer and legend in Biotechnology. He guided, advised and assisted new professional starters in this field, who are ambitioned of starting new companies in this field. He has become a role model and ideal to them. From last 10 years he has been funding new entrants in Biotechnology Industry.
Dr. Lindsay Rosenwald established a company known as Cougar Biotechnology, engaged in clinical research has been sold to Johnson and Johnson Company for a huge amount of 1 billion dollars. His group of companies achieved best track record in the field of Biotechnology and Clinical Research. One example is that they developed a rare medicine for Leukemia which has been approved by FDA for marketing with just 30 clinical trials. This is the best record in Biotechnology Industry. He is also a director in Paramount Technology, Inc., Interneuron Pharmaceuticals, Inc., Keyx, Inc. etc.

History of Dr. Lindsay Rosenwald

2010-04-29T08:24:00.000-07:00

Dr. Lindsay Rosenwald, Chairman of the Paramount Group of companies, is known as among the leading businessmen in division of biotechnology. His accomplishments cover several undertakings, from a company who handles drug development procedures to a bio-sciences corporation where they focus on the introduction of pharmaceutical drug solutions. Also assisting Paramount and its numerous portfolio businesses is Paramount BioCapital, a registered broker-dealer with Financial Industry Regulatory Authority, Inc., or FINRA. Paramount BioCapital raises funds and assistance for Paramount’s portfolio companies and has raised nearly $950,000,000 for these businesses since its inception in 1991.

Right after graduating from Abington High School in southeastern Pennsylvania in 1973, Dr. Rosenwald joined Pennsylvania State University as a Finance major. He graduated in 1977 as a member of Beta Gamma Sigma, a business school honor society, and moved on to Temple University’s School of Medicine. Right after graduating from Temple in 1983, Dr. Rosenwald got an internship at Abington Medical Hospital and remained in private medical practice right up until 1986. At that point, he relocated to Wall Street to serve as a physician/financial expert, a specialized mixture of job areas, which hardly any boasted at that time.

In 1991, Dr. Rosenwald formed Paramount BioCapital, and in the 19 years since then has totally changed the field of bioresearch and biotechnology. One of his businesses holds the patent on a drug that is being fast tracked though the FDA. Cougar Biotechnology, another business launched by Dr. Rosenwald, was acquired by Johnson & Johnson in 2009 based exclusively on abiraterone acetate. This substance wasn't yet in phase III medical trials for its application in the treatment of prostate cancer but was so encouraging that Johnson & Johnson obtained the organization in a “short-term merger” for approximately $1 billion. Abiraterone acetate is also significant as having been influenced by a Traditional Chinese Medicine (TCM) practice. In addition to his activities, which have offered investment capital and financing to many portfolio organizations, Dr. Rosenwald also founded the Rosenwald Foundation, a nonprofit organization that has bequeathed millions of dollars to aid different scientific and medical training establishments. His kind gifts offer the means for scientists to produce the medications of the future.

Dr. Lindsay Rosenwald’s nearly 20-year history in the areas of biotechnology, pharmaceutics, biomedicine, and finance has placed him at the lead of cutting-edge research and improvement. The specific combination of disciplines he studied - medicine and finance - places him in a uncommon and distinctive situation to recognize possibilities to widen the frontiers of high-tech medicine and fund those pioneers that actually work on those frontiers. There are very few people in the world that can match Dr. Rosenwald's remarkable achievements in such a highly specialized industry.

Lindsay Rosenwald & Jewish Heritage Program

2010-02-03T09:10:00.000-08:00

Dr. Lindsay Rosenwald, the Chairman and CEO of Paramount BioCapital, has long been involved with the Jewish Heritage Programs. Paramount BioCapital is a significant figure in the fields of pharmaceuticals and biotechnology. Lindsay Rosenwald has hosted many students in his office for JHP mentoring events, through which students are introduced to many business and industry professionals who advise and mentor them, inspiring them to remain connected with their heritage.

In 2007, Lindsay Rosenwald was recognized and honored by JHP as their “Mentor of the Year.” Dr. Lindsay Rosenwald accepted this honor at an event in June of that year, alongside other notables such as Andrew Schwartz, a recent alumni honoree, and Mr. Jonathan Golub, a Strategist at Bear Stearns and active longtime supporter of JHP.
Since its inception in 1993, this organization has helped over 65,000 Jewish students across 10 colleges. Students who are members create their own events and develop long-term connections to other individuals and the Jewish community.

Through the efforts and assistance of individuals like Dr. Lindsay Rosenwald, JHP has enabled these thousands of Jewish students to feel more connected to their heritage and community.

About Lindsay Rosenwald

2010-01-31T06:53:00.001-08:00

As one of the most productive contributors to the field of biotechnology, Doctor Lindsay Rosenwald’s impact is centered around his Paramount Group of Companies, of which he is the Founder and Chairman. These organizations span a wide spectrum, from Paramount Corporate Development, a company that facilitates and coordinates drug advancement and corporate development activities for Paramount’s group of portfolio companies, to Paramount BioSciences, a multi-national pharmaceutical development and healthcare investment firm focusing on the conception, cultivation, and financial backing of new biotechnology companies. Additionally, supporting Paramount and its many portfolio companies is Paramount BioCapital, a registered broker-dealer with FINRA, which raises capital and support for Paramount’s portfolio companies. To date, Paramount BioCapital has raised nearly $950 million for these companies since its launch in 1991.

Dr. Lindsay Rosenwald graduated from Abington High School, located in southeast Pennsylvania, in 1973, and went on to graduate from Pennsylvania State University with a major in Finance in 1977, graduating Beta Gamma Sigma. After then attending Temple University at their School of Medicine, he interned at Abington Medical Hospital while engaged in private practice. In 1986 his attention turned to Wall Street, where the unique combination of the disciplines of medicine and finance, a specialization that few enjoyed at the time, set him on the path to the massive impact he has had today.

Paramount BioCapital was founded in 1991 and has since then transformed the fields of bioresearch and biotechnology. Ongoing accomplishments around this time include abiraterone acetate, a drug that was being developed by his company Cougar Biotechnology. Cougar was researching this drug’s usage in the treatment of prostate cancer, and was not yet in Phase III clinical trials when Johnson & Johnson purchased Cougar for approximately $1,000,000,000. Also notable is Arsenic Trioxide, a drug developed by one of Dr. Rosenwald’s portfolio companies, which at the time held the record for the drug to move most rapidly from development to FDA approval. Not content to stop with personal accomplishments or direct benefit to his companies and his portfolio companies, Dr. Lindsay Rosenwald also founded the Rosenwald Foundation, a nonprofit fund which has donated millions of dollars to support numerous scientific and medical educational establishments. These funds and grants assist the innovative scientists of today in research and development, shaping the progression of biotechnology into tomorrow.

With his nearly 20-year background in the fields of biotechnology, pharmaceuticals, biomedicine, and finance, Dr. Lindsay Rosenwald is truly placed as the vanguard of cutting-edge research and development. The unique combination of disciplines he studied - finance and medicine - have positioned him in the rare and unique perspective to identify opportunities to expand the frontiers of high-tech medicine and finance those pioneers that work on the forefront of the field. With his rich and varied history in a remarkably specialized industry, Doctor Lindsay Rosenwald’s prolific accomplishments are matched by few in the industry.